{"name":"MingSight Pharmaceuticals, Inc","slug":"mingsight-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPQTRFblotODlULUo0eHkzR0FDaGlvcnFBYjY1OWlIWEhueERJYVA2LXR5b1hxZUVPWlk4V1plMV80Y3BfcF9RSEVkRGNOV0FINmg4bTY5Z2lTaEVncS1XT2RubFplZm81ZndnUmZVbDlJRHVZaWRUTDBhTFpBU3J5M1NEZFRQMHNaZnYzMkNQeXBleXI3Y29PbXY4dHZRbTV0SWxLYTd4T2EyTWF2aGQ5aU1rdkNiamlFTGdpeGVUZEoxOGhsLURzbTFpbmxzallZREJrdXhSN0M3SXo3UXVhT1dMWk5ZdmhER1E?oc=5","date":"2025-04-30","type":"regulatory","source":"PR Newswire","summary":"Roche's Susvimo FDA Approval Marks New Era in Diabetic Macular Edema Treatment Market | DelveInsight - PR Newswire","headline":"Roche's Susvimo FDA Approval Marks New Era in Diabetic Macular Edema Treatment Market | DelveInsight","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPa2RuNF9TUkZmdHRsRXZCUmNrZkRFbnlVTm1uX2FscU5sY0VjR1ptalFwMlBXZHpZdlBRQTFXUGpmV3g1X0RZcl9qQmxPMmQ2Q2VkMWEwVFZBVTZBdG5BbW5hYmxiWTNzMDBCdUVWZV9HUVJrajVYM0VwSWZmUlhlMU5mallVeTZzQ1Q1Y3pveUt1UVAtLS1B?oc=5","date":"2024-01-01","type":"trial","source":"Yahoo Finance","summary":"Propulsion of Small Lymphocytic Lymphoma Clinical Trial Pipeline as Novel and Extensive 80+ Therapies Likely to Enter in the Domain | DelveInsight - Yahoo Finance","headline":"Propulsion of Small Lymphocytic Lymphoma Clinical Trial Pipeline as Novel and Extensive 80+ Therapies Likely to Enter in","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxOY2J1UFV1YjdEZWVZWVZZcEdjd2ZCa0x2bmVMVGpvUW16TzQxUXo1cm5qX1Q2c3dYR0RYNWdBRUNURl9qbjRwaW9kZGdWdExCaWExejlLU3lTcVNKeWk3UmJZUGNTNlNQR0FHU0drSE5Ba3daMjU3ZnNyRkRxNzB5RTZBVzhKalRwUG41cDlXYkdoQkZrQ1VCSWNjYno5ZkJFWi1wVmY0NVlDbEZIQU9mM1BzbmgzU1c0U283WHViZkpFZDBnT3Q1d19HdHhiWm9UTHFDclpoWFY2S2xrbGF2eGtQTDBzSWRRdjhDdUFuazBYRnN3eDVmdTYtc3RvdFNvcWJNVkdCVEJ0MmpGVnVHcUdyZTJzeWNmZ08yWGh6WDg?oc=5","date":"2021-11-12","type":"regulatory","source":"Business Wire","summary":"MingSight Completes a New Round of Financing to Accelerate Clinical Development in Chronic Lymphocytic Leukemia and Diabetic Macular Edema - Business Wire","headline":"MingSight Completes a New Round of Financing to Accelerate Clinical Development in Chronic Lymphocytic Leukemia and Diab","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}